GLP-3RT
RETA is a synthetic peptide that acts as a triple agonist, targeting the Glucagon-like peptide-1 (GLP-1),
Glucose-dependent insulinotropic polypeptide (GIP), and Glucagon (GCG) receptors. In laboratory research, it is utilized to study the potentiation of metabolic signaling and the regulation of nutrient-stimulated hormone secretion. Studies focus on its efficacy in modulating glucose homeostasis and observing the synergistic effects of triple-receptor activation on lipid metabolism in experimental models.
- GLP-1 Receptor: Reduces appetite and improves blood sugar control.
- GIP Receptor: Enhances insulin secretion and optimizes fat metabolism.
- Weight Loss: Phase 2 and ongoing trial data show average weight reductions exceeding 20% to 24%.
- Metabolic Benefits: Improves blood pressure, lipid panels, and helps reduce liver fat in non-alcoholic fatty liver disease (NAFLD).
- Side Effects: Common adverse events are primarily gastrointestinal, including nausea, diarrhea, vomiting, and constipation, alongside transient dose-dependent increases in heart rate












Reviews
There are no reviews yet.